Skip to main content
NoticePayment processing is currently down, so we are not taking new orders right now. Thank you for your patience.
For laboratory research use only. Not for human or veterinary use.
Free UPS Ground on 3+ vials · same business day by 2 PM ET
GLP-1 family

Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial

le Roux CW, Steen O, Lucas KJ, et al. · Lancet Diabetes Endocrinol · 2024
PMID: 38330987 · DOI: 10.1016/S2213-8587(24)00007-X
Summary

Phase 2 dose-finding randomized, double-blind, placebo-controlled trial of once-weekly subcutaneous survodutide (GLP-1/glucagon dual agonist) at 0.6 to 4.8 mg vs placebo, 46 weeks, in 387 adults with obesity. Primary endpoint: percent change in body weight.

Read the full citation on PubMed

Citation hosted by NCBI. We link to the source so the researcher can read the abstract, full text, or references-cited list directly.

More GLP-1 family citations
Browse the catalog